HUTCHISON CHINA MEDITECH LTD filed this 6-K on 07-Aug-2025
HUTCHMED (CHINA) LTD - 6-K - 20250807 - EXHIBIT_99

Exhibit 99.2

Dividends

No dividend has been declared or paid by the Company since its incorporation.

Reconciliation between US GAAP and International Financial Reporting Standards

These interim unaudited condensed consolidated financial statements are prepared in accordance with US GAAP, which differ in certain respects from International Financial Reporting Standards (IFRS). The effects of material differences prepared under US GAAP and IFRS are as follows:

(i)Reconciliation of condensed consolidated statements of operations

    

Six Months Ended June 30, 2025

IFRS adjustments

Tax effects of

intercompany

Amounts as

Lease

unrealized

Capitalization

 reported under 

 amortization 

profit

of rights

Amounts 

    

US GAAP

    

(note (a))

    

(note (b))

    

(note (c))

    

under IFRS

(in US$000)

Cost of goodsthird parties

(147,601)

7

(147,594)

Research and development expenses

(71,990)

40

(16,109)

(88,059)

Selling expenses

 

(13,873)

 

11

 

 

 

(13,862)

Administrative expenses

 

(27,751)

 

26

 

 

 

(27,725)

Total operating expenses

 

(281,191)

 

84

 

 

(16,109)

 

(297,216)

Gain on divestment of an equity investee

477,456

18

(151)

477,323

Other income, net

 

21,650

 

(104)

 

 

 

21,546

Income/(loss) before income taxes and equity in earnings of an equity investee

 

495,592

 

(2)

 

(151)

 

(16,109)

 

479,330

Equity in earnings of an equity investee, net of tax

 

23,125

 

6

 

(91)

 

 

23,040

Net income

 

455,555

 

4

 

(242)

 

(16,109)

 

439,208

Less: Net income attributable to noncontrolling interests

 

(601)

 

3

 

 

25

 

(573)

Net income attributable to the Company

 

454,954

 

7

 

(242)

 

(16,084)

 

438,635

    

Six Months Ended June 30, 2024

IFRS adjustment

Tax effects of

Amounts as 

Lease

intercompany

reported under 

 amortization

unrealized profit

Amounts 

    

US GAAP

    

 (note (a))

    

 (note (b))

    

under IFRS

(in US$000)

Cost of goodsthird parties

(151,681)

31

(151,650)

Research and development expenses

 

(95,256)

 

49

 

 

(95,207)

Selling expenses

 

(27,351)

 

18

 

 

(27,333)

Administrative expenses

 

(30,460)

 

40

 

 

(30,420)

Total operating expenses

 

(333,202)

 

138

 

 

(333,064)

Other income, net

 

22,765

 

(91)

 

 

22,674

Income/(loss) before income taxes and equity in earnings of an equity investee

 

(4,756)

 

47

 

 

(4,709)

Equity in earnings of an equity investee, net of tax

 

33,807

 

6

 

(215)

 

33,598

Net income

 

26,165

 

53

 

(215)

 

26,003

Less: Net income attributable to noncontrolling interests

 

(364)

 

(7)

 

 

(371)

Net income attributable to the Company

 

25,801

 

46

 

(215)

 

25,632

1


(ii)

Reconciliation of condensed consolidated balance sheets

June 30, 2025

IFRS adjustments

Tax effects of

Amounts as 

Lease 

intercompany

reported under 

amortization 

unrealized profit

Issuance costs

LTIP classification

Amounts 

    

US GAAP

    

(note (a))

    

(note (b))

    

(note (d))

    

(note (e))

    

under IFRS

(in US$000)

Investment in an equity investee

3,645

(1)

8

3,652

Other non-current assets

40,620

(74)

40,546

Total assets

 

1,775,940

 

(75)

 

8

 

 

 

1,775,873

Other payables, accruals and advance receipts

 

221,061

 

 

 

 

(71)

 

220,990

Total current liabilities

 

342,349

 

 

 

 

(71)

 

342,278

Total liabilities

 

534,017

 

 

 

 

(71)

 

533,946

Additional paid-in capital

 

1,527,662

 

 

 

(697)

 

71

 

1,527,036

Accumulated losses

 

(380,319)

 

(75)

 

8

 

697

 

 

(379,689)

Accumulated other comprehensive loss

 

(5,490)

 

11

 

 

 

 

(5,479)

Total Companys shareholders equity

 

1,229,064

 

(64)

 

8

 

 

71

 

1,229,079

Non-controlling interests

 

12,859

 

(11)

 

 

 

 

12,848

Total shareholders equity

 

1,241,923

 

(75)

 

8

 

 

71

 

1,241,927

    

December 31, 2024

IFRS adjustments

Tax effects of

intercompany

Amounts as 

Lease 

unrealized

Capitalization

Issuance 

LTIP 

reported under 

amortization 

profit

of rights

costs 

classification 

Amounts 

    

US GAAP

    

(note (a))

    

(note (b))

    

(note (c))

    

(note (d))

    

(note (e))

    

under IFRS

(in US$000)

Investment in an equity investee

77,765

(22)

246

77,989

Other non-current assets

32,378

(52)

14,815

47,141

Total assets

 

1,274,196

 

(74)

 

246

 

14,815

 

 

 

1,289,183

Other payables, accruals and advance receipts

 

256,124

 

 

 

 

 

(493)

 

255,631

Total current liabilities

 

376,562

 

 

 

 

 

(493)

 

376,069

Total liabilities

 

502,343

 

 

 

 

 

(493)

 

501,850

Additional paid-in capital

 

1,517,526

 

 

 

 

(697)

 

493

 

1,517,322

Accumulated losses

 

(833,172)

 

(82)

 

250

 

16,084

 

697

 

 

(816,223)

Accumulated other comprehensive loss

 

(11,585)

 

16

 

(4)

 

(1,294)

 

 

 

(12,867)

Total Companys shareholders equity

 

759,929

 

(66)

 

246

 

14,790

 

 

493

 

775,392

Non-controlling interests

 

11,924

 

(8)

 

 

25

 

 

 

11,941

Total shareholders equity

 

771,853

 

(74)

 

246

 

14,815

 

 

493

 

787,333

2


Notes:

(a)

Lease amortization

Under US GAAP, for operating leases, the amortization of right-of-use assets and the interest expense element of lease liabilities are recorded together as lease expenses, which results in a straight-line recognition effect in the condensed consolidated statements of operations.

Under IFRS, all leases are accounted for like finance leases where right-of-use assets are generally depreciated on a straight-line basis while lease liabilities are measured under the effective interest method, which results in higher expenses at the beginning of the lease term and lower expenses near the end of the lease term.

(b)

Tax effects of intercompany unrealized profit

Under US GAAP, deferred taxes for unrealized profit resulting from intercompany sales of inventory is not recognized.  

Under IFRS, deferred taxes for unrealized profit resulting from an intercompany sale of inventory is recognized at the buyers tax rate.

(c)

Capitalization of development and commercial rights

Under US GAAP, the acquired development and commercial rights do not meet the capitalization criteria as further development is needed as of the acquisition date and there is no alternative future use.  Such rights are considered as IPR&D and were expensed to research and development expense.

Under IFRS, the acquired development and commercial rights were capitalized to intangible assets.  The recognition criterion is always assumed to be met as the price already reflects the probability that future economic benefits will flow to the Group.  For the six months ended June 30, 2025, the intangible asset was impaired after completing an impairment assessment.

(d)

Issuance costs

Under US GAAP and IFRS, there are differences in the criteria for capitalization of issuance costs incurred in the offering of equity securities.

(e)

LTIP classification

Under US GAAP, LTIP awards with performance conditions are classified as liability-settled awards prior to the determination date as they settle in a variable number of shares based on a determinable monetary amount, which is determined upon the actual achievement of performance targets. After the determination date, the LTIP awards are reclassified as equity-settled awards.

Under IFRS, LTIP awards are classified as equity-settled awards, both prior to and after the determination date, as they are ultimately settled in ordinary shares or the equivalent ADS of the Company instead of cash.

3